S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
NYSE:ALVO

Alvotech (ALVO) Stock Price, News & Analysis

$13.22
+0.33 (+2.56%)
(As of 04/19/2024 ET)
Today's Range
$12.75
$14.00
50-Day Range
$11.40
$17.27
52-Week Range
$6.70
$18.00
Volume
1.69 million shs
Average Volume
166,209 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.67

Alvotech MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
4.2% Downside
$12.67 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of Alvotech in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.79) to ($0.23) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.08 out of 5 stars

ALVO stock logo

About Alvotech Stock (NYSE:ALVO)

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

ALVO Stock Price History

ALVO Stock News Headlines

Alvotech expands US reach with biosimilar to Humira
Critical Comparison: Alvotech (ALVO) and Its Rivals
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Alvotech (ALVO) Q4 2023 Earnings Call Transcript
Alvotech Announces Increase in Number of Own Shares
Alvotech Announces Increase in Number of Own Shares
Q4 2023 Alvotech SA Earnings Call
TEVA Mar 2024 10.000 call
TEVA Mar 2024 15.500 put
Alvotech appoints new interim Chief Quality Officer
TEVA Mar 2024 14.500 put
Alvotech Appoints Interim Chief Quality Officer
See More Headlines
Receive ALVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alvotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/20/2024
Today
4/21/2024
Next Earnings (Estimated)
5/17/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Fax
N/A
Employees
1,026
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.67
High Stock Price Target
$20.00
Low Stock Price Target
$8.00
Potential Upside/Downside
-4.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-551,730,000.00
Net Margins
-967.97%
Pretax Margin
-712.04%

Debt

Sales & Book Value

Annual Sales
$93.38 million

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.07
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Faysal Kalmoua (Age 48)
    COO & Director
  • Mr. Robert Wessman (Age 54)
    CEO, Founder & Executive Chairman
    Comp: $740k
  • Mr. Joel Morales (Age 46)
    Chief Financial Officer
  • Mr. Giedrius Zunda
    Chief Technical Officer
  • Mr. Joseph E. McClellan (Age 50)
    Chief Scientific Officer
  • Ms. Tanya Zharov (Age 57)
    General Counsel
  • Mr. Anil Okay (Age 38)
    Chief Commercial Officer
  • Mr. Ming Li (Age 47)
    Chief Strategy Officer
  • Ms. Christina Siniscalchi
    Chief Quality Officer

ALVO Stock Analysis - Frequently Asked Questions

Should I buy or sell Alvotech stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alvotech in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALVO shares.
View ALVO analyst ratings
or view top-rated stocks.

What is Alvotech's stock price target for 2024?

2 brokerages have issued 1 year price targets for Alvotech's stock. Their ALVO share price targets range from $8.00 to $20.00. On average, they expect the company's share price to reach $12.67 in the next twelve months. This suggests that the stock has a possible downside of 4.2%.
View analysts price targets for ALVO
or view top-rated stocks among Wall Street analysts.

How have ALVO shares performed in 2024?

Alvotech's stock was trading at $11.48 at the beginning of the year. Since then, ALVO stock has increased by 15.2% and is now trading at $13.22.
View the best growth stocks for 2024 here
.

When is Alvotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 17th 2024.
View our ALVO earnings forecast
.

How were Alvotech's earnings last quarter?

Alvotech (NYSE:ALVO) announced its quarterly earnings results on Wednesday, March, 20th. The company reported ($1.22) EPS for the quarter, missing analysts' consensus estimates of $0.15 by $1.37. The business had revenue of $18.90 million for the quarter, compared to the consensus estimate of $93 million.

How do I buy shares of Alvotech?

Shares of ALVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ALVO) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners